Immunotech Laboratories Stock

Immunotech Laboratories EV/FCF

EV/FCF (Enterprise Value to Free Cash Flow) of Immunotech Laboratories (IMMB) as of Aug 16, 2026.

EV/FCF

0.00

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Immunotech Laboratories is 2026 0.00 . EV/FCF (Enterprise Value to Free Cash Flow) of Immunotech Laboratories was 2025 -1.26 . It decreases by % higher compared to the previous year.
Access this data via the Eulerpool API

Immunotech Laboratories Stock analysis

What does Immunotech Laboratories do? Immunotech Laboratories Inc is a biotechnology company specializing in the development and marketing of immunotherapies for the treatment of various diseases. The company was founded in 2005 in California, USA. Immunotech Laboratories focuses on the development of immunotherapies for diseases such as HIV/AIDS, Hepatitis C, cancer, and autoimmune diseases. The business model of Immunotech Laboratories is based on the development of innovative immunotherapies using natural compounds. The company collaborates closely with leading scientists and experts in the field of immunology. The developed therapies undergo various clinical trials and are commercially distributed upon successful approval. Immunotech Laboratories specializes in different areas in order to offer a wide range of therapies to its customers. For example, the company develops immunotherapies for the treatment of HIV/AIDS. Immunotech Laboratories combines different compounds to reduce viral load in the body and aid the immune system in fighting the infection. Another important area for Immunotech Laboratories is the development of immunotherapies for cancer treatment. The company utilizes innovative approaches that enable the body's natural defenses to recognize and combat cancer cells. Combination of different compounds is also employed to enhance effectiveness. In addition to these areas, Immunotech Laboratories also offers immunotherapies for the treatment of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company employs innovative approaches that enable the immune system to recognize and fight pathogens causing these diseases. Immunotech Laboratories offers a range of products developed based on immunotherapies. These include different combinations of compounds for the treatment of HIV/AIDS and Hepatitis C, as well as immunotherapies for cancer and autoimmune diseases. These products are available in the form of injections, capsules, or tablets and can be prescribed by physicians. Overall, Immunotech Laboratories is an innovative biotechnology company specializing in the development and marketing of immunotherapies. The company collaborates with leading experts in immunology and develops innovative approaches for the treatment of various diseases. The offered products are known for their high effectiveness and tolerability, helping patients worldwide improve their health. Immunotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunotech Laboratories stock

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Immunotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Immunotech Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Immunotech Laboratories

All Key Metrics — Immunotech Laboratories